• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    PCI Pharma Services

    Reed-Lane

    Aphena Pharma Solutions

    Adare Pharma Solutions

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Quotient Sciences

    Adare Pharma Solutions

    Baxter BioPharma Solutions

    Aphena Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Moore’s Law for More Health

    This year marks the semicentennial anniversary of a prediction about exponential growth and productivity

    Related CONTENT
    • Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Crystec Launches New R&D Center in China
    • The Ever-Evolving World of Combination Products
    • RBQM Comes of Age: COVID as a Catalyst for Change
    Patrick Jordan , Encore Health Resources06.02.15
    In 1965, Gordon Moore, co-founder of Intel, predicted that the number of transistors per square inch of integrated circuits would double each year for the foreseeable future. It was a bold claim—the integrated circuit had only been around for seven years, so there was little history on which to base his forecast. But it proved accurate for so long and was so remarkable in representing a phenomenon that could transform a transistor that fit in the palm of the hand to something so small that 4,000 could fit across the width of a human hair, it became a law of sorts—Moore’s Law. More an aspiration than a law of nature, Moore’s Law is the definitive benchmark to measure the productivity gains achieved across a range of technical processes, from developing photo cells to brewing beer.

    Moore’s Law has been applied to the life sciences, sometimes to great success. For several years in the early 2000s, the cost to sequence the human genome tracked Moore’s Law. The National Human Genome Research Institute calculated the cost of sequencing the genome at nearly $100 million in 2001. In just six years, that cost dropped to under $10 million, in line with Moore’s Law. Productivity got even better over the next seven years, when costs dropped to less than $5,000, a far better improvement than Moore’s Law would have predicted.

    But the wider sphere of drug development has not always enjoyed this type of exponential improvement. For a time, Moore’s Law was applied to drug development in reverse. Calling the phenomenon Eroom’s Law—Moore’s Law spelled backwards—Jack Scannell wrote in a 2012 paper in Nature Reviews Drug Discovery that the number of new drugs approved by the FDA per billion of inflation-adjusted U.S. dollars has halved about every nine years, suggesting that drug development was worsening. At the 2012 Forbes Healthcare Summit, several pharma execs saw Eroom’s Law ending, due to improved technology, availability of biomarkers, and insights from genomics. Recent drug approval data give an encouraging sign of that improvement, with 41 new drugs approved in 2014, the highest level in the past decade.

    The trouble is, progress in drug development is increasingly measured by more than drug approvals. Successful products today demonstrate safety and efficacy, meet an unmet need, achieve favorable reimbursement, and reduce the total cost of care—a complicated combination of goals that relate to a system of healthcare stakeholders. Achieving one goal while ignoring the others reduces the overall impact that promising new treatments can have on the healthcare system, whether that impact is measured in financial returns or lives improved. Connecting insights across the system helps ensure that the whole of the healthcare system improves as fast as the sum of its parts.

    With homage to Dr. Moore and to the impressive gains that technology systems have achieved in 50 years, below are a few ideas to advance an interconnected system of healthcare.

    Prepare For a New Healthcare Operating System
    Containing the cost of healthcare requires new ways of operating, and most stakeholders believe it will come from working more closely together. In 2013, Quintiles published The Collaboration Mandate on the impact of healthcare’s changing landscape on the relationships of providers, payers, and biopharmaceutical companies. According to the surveys, less than 20% of these stakeholder groups thought they were aligned with others, but well over half expect to be in the next several years. Despite the challenges with aligning around incentives, about 75% of the stakeholders believed that working in a system presents an opportunity to improve healthcare. But the stakeholders need to figure out how to share data to make the system work. More than 70% said transparency around data and information sharing across stakeholders was vitally important to the success of an interconnected healthcare system, yet less than half thought they had the tools or expertise to optimize its use.

    Backwards Compatibility Can Be The Way Forward
    Oncology is the most prolific therapeutic area in the development pipeline and one of the most challenging with the lowest likelihood of approval. Challenge creates opportunity, even in discoveries that first seem like failures. In a recent opinion piece, Peter Huber and Paul Howard at the Manhattan Institute referred to a 2010 study where more than 90% of bladder cancer patients failed to respond to an experimental treatment, while one patient had “no evidence of disease” two years later. This positive result arose because of a biomarker found in 8% of bladder cancer patients that made her cancer sensitive to the experimental treatment. Reviewing other failed studies, the National Cancer Institute identified 100 responders where biomarkers may revive shelved products, the life sciences equivalent of backwards compatibility. As genomic capabilities mature, we can do more to prospectively identify unique patient populations and speed development of therapeutics suited for them. Work is already underway at places like Memorial Sloan Kettering Cancer Center with “basket trials,” which reverse the typical process of studying a specific organ first and instead examine cancers of different organs whose tumors share the same genetic mutation.

    Engage Communities
    I recently had the privilege to speak with a mother who enrolled her daughter in a trial to study a treatment for a rare and often fatal bone disease. Her experience was heart-wrenching, learning during pregnancy that her unborn daughter would not likely live beyond birth. As it was hopeful, with her baby girl beating the odds to survive and ultimately receiving an experimental treatment that helped her bones harden, making her capable of not only walking but also running. I asked this mom what more the drug development industry could do to help her and her inspiring daughter. I expected a request for more research of rare diseases and an impatience among those in the industry to find cures, both of which are certainly needed, but she did not ask for that. Instead, she asked that we help connect families going through the same harrowing experience so they can navigate the clinical research and healthcare systems together. We often first think of science as the means to take healthcare forward, but community helps make sure patients and families are not left behind.

    Optimize the Experience
    Chief Experience Officer sounds more like a role from a tech startup than healthcare. In 2007, Cleveland Clinic was among the first major academic institution to appoint a Chief Experience Officer (CXO), in response to having some of the lowest patient satisfaction scores in the country. In a few years, the clinic would be in the top 8%. Such an improvement is significant to a hospital’s economics since patient satisfaction scores are a factor in the amount Medicare reimburses. We would also do well to have CXOs that focus on patient satisfaction in clinical trial design. A recent study of oncology trials indicated that physicians under-reported as much as 75% the number of patients who had six common side effects to chemotherapy. As drugs reach the market, side effects drive down drug adherence, a problem thought to cost $100-300 billion each year. But patient experience goes beyond economics. One analysis of 55 studies across disease areas found patient experience in care settings to be positively associated with safety and clinical effectiveness. Another study of nearly 6,500 patients with acute myocardial infarction found that higher patient satisfaction was associated with better guideline adherence and lower inpatient mortality. We know that physician experience matters, but patient experience matters too.

    The Gates Foundation, which focuses on global health among other priorities to promote equity for people around the world, described in its 2015 Annual Letter that it would place a big bet for the future of health. Whereas it previously took 25 years to cut the child death rate in half, the Foundation would cut that rate in half again in 15 years, an achievement of exponential improvement. It is fitting that the Foundation’s bet rests on applying to healthcare “close to the same amount of innovation that goes into making computers faster and smaller.”

    Healthcare needs this type of systems thinking—and more than a few bold prognosticators with a vision for the future where there is a Moore’s Law for more health. 


    Patrick Jordan is vice president of payer and provider services at Encore Health Resources.
    Related Searches
    • Development
    • biopharmaceutical companies
    • Pharma
    • Clinical Trial
    Suggested For You
    Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals Hitachi, Axcelead to Develop Next-Gen Biopharmaceuticals
    Sterling Pharma Solutions Acquires ADC Biotechnology Sterling Pharma Solutions Acquires ADC Biotechnology
    Crystec Launches New R&D Center in China Crystec Launches New R&D Center in China
    The Ever-Evolving World of Combination Products The Ever-Evolving World of Combination Products
    RBQM Comes of Age: COVID as a Catalyst for Change RBQM Comes of Age: COVID as a Catalyst for Change
    Eloxx Pharmaceuticals Acquires Zikani Therapeutics Eloxx Pharmaceuticals Acquires Zikani Therapeutics
    On-Demand Webinar: Accelerated Timelines for Clinical Supply Manufacture On-Demand Webinar: Accelerated Timelines for Clinical Supply Manufacture
    Advanced Analytics Advancing Development of Genetic Vaccines Advanced Analytics Advancing Development of Genetic Vaccines
    Chime Biologics Expands CDMO Capabilities Chime Biologics Expands CDMO Capabilities
    Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise Accelerate Your Program: Streamlined Phase Appropriate Technologies & Expertise
    Regulatory Practices in a Post-Pandemic World Regulatory Practices in a Post-Pandemic World
    Selexis, Pandion Enter Antibody Service Agreement Selexis, Pandion Enter Antibody Service Agreement
    Gilead and Merck Ink HIV Agreement Gilead and Merck Ink HIV Agreement
    NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein
    Aptamer Extends Collaboration with AstraZeneca Aptamer Extends Collaboration with AstraZeneca

    Related Features

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Drug Development | Drug Discovery | R&D
      R&D Outsourcing Trends

      R&D Outsourcing Trends

      Highly specialized drug products and capacity needs drive increased reliance on contract service providers.
      Kristin Brooks, Managing Editor, Contract Pharma 10.14.20

    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20


    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Drug Development | Regulatory Affairs
      Guidelines in Toxicology: A Blessing and a Curse

      Guidelines in Toxicology: A Blessing and a Curse

      A look at the evolution of drug development regulatory guides.
      Sarah Gould, Senior Principal Scientific Advisor, Charles River 09.16.19


    • Drug Discovery
      Drug Discovery Technology Trends

      Drug Discovery Technology Trends

      Combining native mass spectrometry with fragment-based drug discovery in medicinal chemistry
      Sally-Ann Poulsen, Professor of Chemical Biology, Griffith Institute for Drug Discovery (GRIDD), Griffith University 09.16.19

    • Drug Development
      Flex Your Outsourcing Model to Maximize Drug Development

      Flex Your Outsourcing Model to Maximize Drug Development

      How to choose—and optimize—combinations of service models to fit your needs.
      Timothy King, Executive Director, Functional Service Partnerships (FSP), PPD 09.16.19

    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19


    • Drug Development
      Improving Your Development Program

      Improving Your Development Program

      Seven lab science trends driving the future of drug development.
      Jenifer Vija, Liam Moran, Chris Loosbroock and Eric Snyder, Charles River 05.07.19

    • Drug Development
      Technical Advantages of Continuous Flow Chemical Synthesis

      Technical Advantages of Continuous Flow Chemical Synthesis

      Continuous flow chemistry is known for its ability to handle hazardous reactions safely, but can also unlock many other technological benefits.
      Shawn Conway, Engineering R&D Director, Cambrex High Point 04.05.19

    • Drug Development | Preclinical Outsourcing
      Early Development Trends

      Early Development Trends

      Catalent’s president of oral drug delivery, Jonathan Arnold, talks trends and challenges in the early phases of drug development.
      Tim Wright, Editor, Contract Pharma 03.06.19


    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19

    • APIs | Cytotoxics and High Potency Manufacturing | Drug Development
      CDMOs On The Rise

      CDMOs On The Rise

      Tracking growth and strategies in the CDMO business
      Michel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19

    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Ascendia Pharmaceuticals Poised For Expansion
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies to Sponsor and Exhibit at the North American Pultrusion Conference 2021
    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands Beautiful Fragrance Collection
    The Honest Company Files for IPO
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login